安进公司的 MariTide 2 期研究显示血糖和体重 "显著 "下降

路透中文
Jan 13
<a href="https://laohu8.com/S/AMGN">安进</a>公司的 MariTide 2 期研究显示血糖和体重 "显著 "下降

路透1月13日 - 安进公司(Amgen AMGN.O)周一称,对2型糖尿病患者进行的一项为期24周的试验性肥胖症药物MariTide月剂量研究显示,血糖和体重均有 "稳健而有临床意义 "的下降。

该公司表示,在一项为期 52 周的扩展研究中,绝大多数接受较低月剂量或季度剂量治疗的参与者都保持了在最初的第二阶段试验中取得的体重减轻效果。

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10